{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:23:13Z","timestamp":1791267793634,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Cancer Vaccine Tracking project","award":["03O-302"],"award-info":[{"award-number":["03O-302"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.jconrel.2015.02.006","type":"journal-article","created":{"date-parts":[[2015,2,7]],"date-time":"2015-02-07T15:06:09Z","timestamp":1423321569000},"page":"16-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"special_numbering":"C","title":["Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation"],"prefix":"10.1016","volume":"203","author":[{"given":"Sima","family":"Rahimian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke F.","family":"Fransen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Willem","family":"Kleinovink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonatan Riis","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Amidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim E.","family":"Hennink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferry","family":"Ossendorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2015.02.006_bb0005","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0010","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: from basic studies to clinical application","volume":"2","author":"zur Hausen","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J. Pathol."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0020","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.20244","article-title":"Against which human papillomavirus types shall we vaccinate and screen? The international perspective","volume":"111","author":"Munoz","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0025","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0030","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/ncponc0770","article-title":"Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing","volume":"4","author":"Wheeler","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0035","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18L1 virus-like particle vaccine among young women with preexisting infection \u2014 a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0040","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1067\/mjd.2000.107807","article-title":"Human papillomavirus infections: epidemiology, pathogenesis, and host immune response","volume":"43","author":"Tyring","year":"2000","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-3-642-38965-8_9","article-title":"Control of HPV infection and related cancer through vaccination","volume":"193","author":"Tran","year":"2014","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0050","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/14728214.2012.744393","article-title":"Emerging human papillomavirus vaccines","volume":"17","author":"Ma","year":"2012","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0055","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.2174\/156802612802652402","article-title":"Advances in peptide-based human papillomavirus therapeutic vaccines","volume":"12","author":"Liu","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0060","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4161\/hv.5.10.9370","article-title":"Different spectra of therapeutic vaccine development against HPV infections","volume":"5","author":"Bolhassani","year":"2009","journal-title":"Hum. Vaccin."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00002371-200003000-00010","article-title":"Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma","volume":"23","author":"Ressing","year":"2000","journal-title":"J. Immunother."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0070","first-page":"3406","article-title":"A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive","volume":"6","author":"Muderspach","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0075","doi-asserted-by":"crossref","first-page":"7855","DOI":"10.1073\/pnas.93.15.7855","article-title":"Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction","volume":"93","author":"Toes","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0080","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.addr.2005.11.003","article-title":"Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy","volume":"58","author":"van der Burg","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0085","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1586\/14760584.6.4.591","article-title":"Design and development of synthetic peptide vaccines: past, present and future","volume":"6","author":"Bijker","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0090","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.4049\/jimmunol.156.10.3911","article-title":"Enhanced tumor outgrowth after peptide vaccination \u2014 functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors","volume":"156","author":"Toes","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0095","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.4049\/jimmunol.179.8.5033","article-title":"CD8(+) CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity","volume":"179","author":"Bijker","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0100","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4049\/jimmunol.169.1.350","article-title":"Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides","volume":"169","author":"Zwaveling","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0105","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1002\/eji.201343324","article-title":"Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation","volume":"43","author":"Rosalia","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0110","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/eji.200737995","article-title":"Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation","volume":"38","author":"Bijker","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0115","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrc2373","article-title":"Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines","volume":"8","author":"Melief","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0120","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/1078-0432.CCR-07-1880","article-title":"Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine","volume":"14","author":"Welters","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0125","first-page":"S19-S19","article-title":"Therapeutic HPV 16 vaccination with long E6 and E7 peptides shows immunological and clinical efficacy","volume":"108","author":"Kenter","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0130","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1586\/14760584.1.1.111","article-title":"Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines","volume":"1","author":"Aucouturier","year":"2002","journal-title":"Expert Rev. Vaccines"},{"issue":"Suppl. 2","key":"10.1016\/j.jconrel.2015.02.006_bb0140","first-page":"S2-44-5","article-title":"The use of oil adjuvants in therapeutic vaccines","volume":"24","author":"Aucouturier","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jconrel.2013.03.010","article-title":"Immune system targeting by biodegradable nanoparticles for cancer vaccines","volume":"168","author":"Silva","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0150","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1172\/JCI23373","article-title":"Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909","volume":"115","author":"Speiser","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0155","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1034\/j.1600-0625.2002.110204.x","article-title":"Induction of skewed Th1\/Th2 T-cell differentiation via subcutaneous immunization with Freund's adjuvant","volume":"11","author":"Shibaki","year":"2002","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0160","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/90609","article-title":"Toll-like receptors: critical proteins linking innate and acquired immunity","volume":"2","author":"Akira","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0165","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1034\/j.1600-065X.2002.18816.x","article-title":"Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes","volume":"188","author":"Melief","year":"2002","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0170","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1158\/1078-0432.CCR-07-0274","article-title":"Toll-like receptor 3 expressed by melanoma cells as a target for therapy?","volume":"13","author":"Salaun","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0175","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.08.002","article-title":"TLR-based immune adjuvants","volume":"29","author":"Steinhagen","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0180","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.addr.2013.05.013","article-title":"Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant","volume":"64","author":"Hafner","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0185","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.vaccine.2008.01.030","article-title":"TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses","volume":"26","author":"Schlosser","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0190","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1016\/j.vaccine.2008.07.035","article-title":"Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8(+) T cell-mediated anti-tumor immunity","volume":"26","author":"Hamdy","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0195","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijpharm.2008.08.039","article-title":"Poly(I:C) coated PLGA microparticles induce dendritic cell maturation","volume":"365","author":"Wischke","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0200","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1039\/B914943K","article-title":"Designing polymeric particles for antigen delivery","volume":"40","author":"De Koker","year":"2011","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0205","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1016\/S0264-410X(01)00111-6","article-title":"A phase I clinical trial of a mufti-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers","volume":"19","author":"Toledo","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0210","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0264-410X(93)90190-9","article-title":"Adjuvants \u2014 a balance between toxicity and adjuvanticity","volume":"11","author":"Gupta","year":"1993","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0215","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1021\/ma052128c","article-title":"Functionalized poly(alpha-hydroxy acid)s via ring-opening polymerization: toward hydrophilic polyesters with pendant hydroxyl groups","volume":"39","author":"Leemhuis","year":"2006","journal-title":"Macromolecules"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0220","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1021\/bm700476h","article-title":"In vitro hydrolytic degradation of hydroxyl-functionalized poly(alpha-hydroxy acid)s","volume":"8","author":"Leemhuis","year":"2007","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0225","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11095-011-0517-3","article-title":"Controlled release of octreotide and assessment of peptide acylation from poly(D, l-lactide-co-hydroxymethyl glycolide) compared to plga microspheres","volume":"29","author":"Ghassemi","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0230","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.1016\/j.biomaterials.2012.06.013","article-title":"The microclimate pH in poly(D, l-lactide-co-hydroxymethyl glycolide) microspheres during biodegradation","volume":"33","author":"Liu","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0235","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.biomaterials.2014.10.043","article-title":"Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: in vivo tracking and evaluation of antigen-specific CD8+ T cell immune response","volume":"37","author":"Rahimian","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2014.12.014","article-title":"Biocompatibility of poly(d, l-lactic-co-hydroxymethyl glycolic acid) microspheres after subcutaneous and subcapsular renal injection","author":"Kazazi-Hyseni","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0245","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ejpb.2012.11.006","article-title":"Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: low-burst release is crucial for efficient CD8(+) T cell activation","volume":"83","author":"Silva","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0250","series-title":"PLGA Microparticle Based Vaccine Carriers for an Improved and Efficacious Tumor Therapy","author":"Krishnamachari","year":"2011"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0255","first-page":"21","article-title":"Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen","volume":"56","author":"Lin","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0260","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.4049\/jimmunol.1201540","article-title":"Vaccine-induced effector-memory cd8(+) t cell responses predict therapeutic efficacy against tumors","volume":"189","author":"van Duikeren","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0265","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1126\/science.274.5284.94","article-title":"Phenotypic analysis of antigen-specific T lymphocytes","volume":"274","author":"Altman","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0270","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jconrel.2007.09.013","article-title":"Nano\/micro technologies for delivering macromolecular therapeutics using poly(D, l-lactide-co-glycolide) and its derivatives","volume":"125","author":"Mundargi","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0275","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0169-409X(93)90046-7","article-title":"Nanoparticles and microparticles for the delivery of polypeptides and proteins","volume":"10","author":"Couvreur","year":"1993","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0280","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.2147\/IJN.S29506","article-title":"PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses","volume":"7","author":"Ma","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0285","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1016\/j.biomaterials.2011.01.067","article-title":"Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery","volume":"32","author":"Zhang","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0290","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0168-3659(99)00275-8","article-title":"Formulation of poly(d, l-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery","volume":"66","author":"Tinsley-Bown","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0295","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s11095-010-0073-2","article-title":"Critical evaluation of nanoparticle tracking analysis (nta) by nanosight for the measurement of nanoparticles and protein aggregates","volume":"27","author":"Filipe","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0300","doi-asserted-by":"crossref","first-page":"7857","DOI":"10.1016\/j.vaccine.2011.07.090","article-title":"A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors","volume":"29","author":"Wick","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2015.02.006_bb0305","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.canep.2012.10.005","article-title":"Enhanced anti-tumor effects of HPV16E7(49\u201357)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150","volume":"37","author":"Chen","year":"2013","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.jconrel.2015.02.006_bb0310","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00262-005-0114-6","article-title":"Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model","volume":"55","author":"Cui","year":"2006","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365915000966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365915000966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T20:02:29Z","timestamp":1691092949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365915000966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":62,"alternative-id":["S0168365915000966"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.02.006","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}